Barclays Issues Pessimistic Forecast for Sotera Health (NASDAQ:SHC) Stock Price

Sotera Health (NASDAQ:SHC) had its target price trimmed by Barclays from $17.00 to $16.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 target price on the stock. Citigroup increased their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Sotera Health currently has an average rating of “Moderate Buy” and a consensus target price of $15.92.

Sotera Health Stock Performance

Shares of SHC stock opened at $12.47 on Friday. The firm’s 50 day moving average price is $13.45 and its 200-day moving average price is $14.51. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a one year low of $10.71 and a one year high of $17.08. The firm has a market cap of $3.53 billion, a P/E ratio of 49.88 and a beta of 1.91.

Institutional Investors Weigh In On Sotera Health

Large investors have recently modified their holdings of the company. Blue Trust Inc. increased its position in shares of Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after purchasing an additional 1,140 shares during the last quarter. True Wealth Design LLC purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $32,000. Quarry LP purchased a new stake in shares of Sotera Health in the 4th quarter valued at approximately $28,000. GAMMA Investing LLC increased its position in shares of Sotera Health by 37.5% in the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock valued at $56,000 after purchasing an additional 1,121 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Sotera Health in the 3rd quarter valued at approximately $91,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.